Hanmi Pharm Co Ltd
KRX:128940
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
264 500
366 169.2238
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hanmi Pharm Co Ltd
Hanmi Pharm Co Ltd
Cash & Cash Equivalents
Hanmi Pharm Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash & Cash Equivalents
₩47.9B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
|
Yuhan Corp
KRX:000100
|
Cash & Cash Equivalents
₩229.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash & Cash Equivalents
₩239.7B
|
CAGR 3-Years
59%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Cash & Cash Equivalents
₩50.6B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
11%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash & Cash Equivalents
₩134B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Cash & Cash Equivalents
₩28.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
66%
|
CAGR 10-Years
28%
|
|
Hanmi Pharm Co Ltd
Glance View
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2010-07-30. The firm operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.
See Also
What is Hanmi Pharm Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
47.9B
KRW
Based on the financial report for Jun 30, 2024, Hanmi Pharm Co Ltd's Cash & Cash Equivalents amounts to 47.9B KRW.
What is Hanmi Pharm Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-4%
Over the last year, the Cash & Cash Equivalents growth was -68%. The average annual Cash & Cash Equivalents growth rates for Hanmi Pharm Co Ltd have been -35% over the past three years , -11% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
